Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cadence Design Systems Inc (CDNS) vs Heron Therapeutics Inc (HRTX) Price & Performance

Cadence Design Systems IncTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Cadence Design Systems Inc vs Heron Therapeutics Inc — how do they compare? Cadence Design Systems Inc trades at $382.36 (market cap $104.24B), while Heron Therapeutics Inc trades at $0.42 (market cap $82.52M). The key difference: Cadence Design Systems Inc is far larger — about 1263.2× Heron Therapeutics Inc's market cap, and Cadence Design Systems Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

CDNSHRTX
Market Cap
$104.24B$82.52M
Sector
TechnologyHealth
52-Week High
$416.39$2.04
52-Week Low
$265.66$0.39
Enterprise Value
$105.91B$180.42M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cadence Design Systems Inc

Cadence Design Systems (CDNS) trades at $377.92, down 1.63% on the day, with strong analyst support (84% buy ratings) and a $400.25 consensus price target. The stock shows bullish technical signals with support at $373 and resistance at $385. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 results expected on July 27, 2026. Revenue growth remains robust, climbing from $3.6B in 2022 to $5.3B in 2025, though profit margins have moderated slightly.

CDNS presents a compelling growth story driven by AI and semiconductor design demand, with upside to analyst targets. However, high valuation multiples (P/E 88.09, P/S 18.68) pose risks if growth slows. Key near-term catalyst is Q2 earnings; sustained execution is critical to justify premium valuation amid competitive pressures.

Heron Therapeutics Inc

HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.

While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.

Returns comparison

Trailing returns across standard periods

About Cadence Design Systems Inc

Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.

Read more on CDNS

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX